SG11201605597VA - Duocarmycin adcs for use in treatment of endometrial cancer - Google Patents
Duocarmycin adcs for use in treatment of endometrial cancerInfo
- Publication number
- SG11201605597VA SG11201605597VA SG11201605597VA SG11201605597VA SG11201605597VA SG 11201605597V A SG11201605597V A SG 11201605597VA SG 11201605597V A SG11201605597V A SG 11201605597VA SG 11201605597V A SG11201605597V A SG 11201605597VA SG 11201605597V A SG11201605597V A SG 11201605597VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- endometrial cancer
- duocarmycin
- adcs
- duocarmycin adcs
- Prior art date
Links
- 206010014733 Endometrial cancer Diseases 0.000 title 1
- 206010014759 Endometrial neoplasm Diseases 0.000 title 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 title 1
- 229960005501 duocarmycin Drugs 0.000 title 1
- 229930184221 duocarmycin Natural products 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14150791 | 2014-01-10 | ||
PCT/EP2015/050332 WO2015104373A2 (en) | 2014-01-10 | 2015-01-09 | Duocarmycin adcs for use in treatment of endometrial cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605597VA true SG11201605597VA (en) | 2016-08-30 |
Family
ID=49917013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605597VA SG11201605597VA (en) | 2014-01-10 | 2015-01-09 | Duocarmycin adcs for use in treatment of endometrial cancer |
Country Status (20)
Country | Link |
---|---|
US (2) | US9427480B2 (zh) |
EP (1) | EP2948183B1 (zh) |
JP (1) | JP6224268B2 (zh) |
KR (2) | KR20160099725A (zh) |
CN (1) | CN105899237B (zh) |
AU (1) | AU2015205588B2 (zh) |
CA (1) | CA2935430C (zh) |
CL (1) | CL2016001743A1 (zh) |
CY (1) | CY1117712T1 (zh) |
DK (1) | DK2948183T3 (zh) |
ES (1) | ES2578831T3 (zh) |
HR (1) | HRP20160797T1 (zh) |
HU (1) | HUE029672T2 (zh) |
MX (1) | MX368234B (zh) |
MY (1) | MY189713A (zh) |
PL (1) | PL2948183T3 (zh) |
PT (1) | PT2948183T (zh) |
RU (1) | RU2686085C2 (zh) |
SG (1) | SG11201605597VA (zh) |
WO (1) | WO2015104373A2 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
AU2009320481C1 (en) | 2008-11-03 | 2016-12-08 | Syntarga B.V. | Novel CC-1065 analogs and their conjugates |
RU2578719C9 (ru) | 2010-04-21 | 2016-10-10 | Синтарга Б.В. | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры |
PL3092010T3 (pl) | 2014-01-10 | 2019-01-31 | Synthon Biopharmaceuticals B.V. | Sposób oczyszczania połączonych cysteiną koniugatów przeciwciało-lek |
PL3069735T3 (pl) * | 2014-01-10 | 2018-08-31 | Synthon Biopharmaceuticals B.V. | ADC duokarmycyny do zastosowania w leczeniu raka pęcherza |
CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
PL3151865T3 (pl) | 2014-05-22 | 2022-01-03 | Byondis B.V. | Koniugacja w określonym miejscu leków-łączników z przeciwciałami oraz powstałe w jej wyniku koniugaty przeciwciało-lek (ADCs) |
TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
JP6522806B2 (ja) | 2015-07-10 | 2019-05-29 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 抗体デュオカルマイシン薬物複合体を含む組成物 |
JP6607634B2 (ja) * | 2015-09-04 | 2019-11-20 | 学校法人 岩手医科大学 | 腫瘍の再発を抑制するための標的分子としてのtaf15遺伝子およびその産物 |
KR101704379B1 (ko) * | 2015-10-27 | 2017-02-08 | (주)알테오젠 | 항체-약물 접합체 및 그 제조방법 |
DE102016105449A1 (de) * | 2015-10-29 | 2017-05-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Bifunktionale Prodrugs |
US10668166B2 (en) | 2016-05-30 | 2020-06-02 | Toxinvent Ou | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
RS64690B1 (sr) | 2018-03-13 | 2023-11-30 | Zymeworks Bc Inc | Konjugati biparatopskog anti-her2 antitela i leka i postupci za njihovu upotrebu |
US20210369705A1 (en) | 2018-10-15 | 2021-12-02 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
US20220387618A1 (en) | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
US20230092648A1 (en) * | 2020-02-06 | 2023-03-23 | Byondis B.V. | Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate |
WO2024127332A1 (en) | 2022-12-14 | 2024-06-20 | Pheon Therapeutics Ltd | Cytotoxic compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1238907A (en) | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
US4771128A (en) | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
MX9203460A (es) | 1988-09-12 | 1992-09-01 | Upjohn Co | Nuevos analogos cc-1065 que tienen dos subunidades cpi. |
AU648313B2 (en) | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
JPH05268205A (ja) | 1992-03-19 | 1993-10-15 | Fujitsu Ltd | クロック切換え回路 |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
JP3514490B2 (ja) | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法 |
GB9307491D0 (en) | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
AU689566B2 (en) | 1994-04-01 | 1998-04-02 | Kyowa Hakko Kogyo Co. Ltd. | DC-89 derivatives |
US5502068A (en) | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
DE19503320A1 (de) | 1995-02-02 | 1996-08-08 | Boehringer Mannheim Gmbh | Neue Benzodiazepinkonjugate |
US5843937A (en) | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
EP0938474B1 (en) | 1996-09-12 | 2005-11-23 | Auckland Uniservices Limited | Cyclopropylindole compounds and their use as prodrugs |
WO1998025900A1 (fr) | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Composes presentant une activite antitumorale |
US20030036629A1 (en) | 1997-12-12 | 2003-02-20 | Barry Foster | Novel tgf-beta protein purification methods |
DE50104114D1 (de) | 2000-05-02 | 2004-11-18 | Tietze Lutz F | Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie |
JP5010089B2 (ja) | 2000-09-19 | 2012-08-29 | スピロジェン リミテッド | Cc−1065およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法 |
EP1363908A4 (en) | 2001-01-24 | 2004-05-06 | Auckland Uniservices Ltd | ANTI-CANCER COMPLEXES 2,3-DIHYDRO-1H-PYRROLO 3,2-F] COBALT AND CHROME QUINOLINE |
US7192977B2 (en) | 2001-02-22 | 2007-03-20 | School Of Pharmacy | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
CN101671335A (zh) * | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
WO2003022806A2 (en) | 2001-09-07 | 2003-03-20 | The Scripps Research Institute | Cbi analogues of cc-1065 and the duocarmycins |
WO2003026577A2 (en) * | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
AU2003228173A1 (en) | 2002-05-17 | 2003-12-02 | Auckland Uniservices Limited | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-(ring fused indol-5-yl(amine-derived)) compounds and analogues thereof, and to products obtained therefrom |
US20050180972A1 (en) * | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
CA2506080A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
WO2004069201A2 (en) | 2003-02-03 | 2004-08-19 | Medlogics Device Corporation | Compounds useful in coating stents to prevent and treat stenosis and restenosis |
DK1594542T3 (da) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer |
US20050026987A1 (en) | 2003-05-13 | 2005-02-03 | The Scripps Research Institute | CBI analogues of the duocarmycins and CC-1065 |
WO2005032594A2 (en) | 2003-10-03 | 2005-04-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alkylators linked to polyamides as dna binding agents |
ES2533695T3 (es) * | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
MXPA06013413A (es) | 2004-05-19 | 2007-01-23 | Medarex Inc | Enlazadores quimicos y conjugados de los mismos. |
US20100202941A1 (en) | 2004-07-02 | 2010-08-12 | Hideki Chikada | Liquid Fuel Reforming Device |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
WO2006037052A2 (en) | 2004-09-27 | 2006-04-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Modulating mxa expression |
NZ536107A (en) | 2004-10-22 | 2007-06-29 | Auckland Uniservices Ltd | Nitrobenzindoles and their use in cancer therapy |
JP2008531542A (ja) | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | 抗癌剤として有用な二環式複素芳香族誘導体 |
EA016577B1 (ru) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
DK1940789T3 (da) | 2005-10-26 | 2012-03-19 | Medarex Inc | Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger |
MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
AU2007322261B2 (en) | 2006-11-01 | 2014-01-23 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
EP2121667B1 (en) | 2007-02-21 | 2016-06-08 | E. R. Squibb & Sons, L.L.C. | Chemical linkers with single amino acids and conjugates thereof |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
EP2173739B1 (en) | 2007-08-01 | 2013-07-31 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
ES2441115T3 (es) | 2007-11-13 | 2014-01-31 | The Scripps Research Institute | Derivados de CBI sujetos a activación reductora |
US20090162372A1 (en) | 2007-11-30 | 2009-06-25 | Medarex, Inc. | Fibronectin ed-b antibodies, conjugates thereof, and methods of use |
NZ571028A (en) | 2008-09-03 | 2011-01-28 | Auckland Uniservices Ltd | Nitrobenzindole compounds and their use in cancer treatment |
JP5675619B2 (ja) | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
AU2009320481C1 (en) | 2008-11-03 | 2016-12-08 | Syntarga B.V. | Novel CC-1065 analogs and their conjugates |
WO2011022316A1 (en) | 2009-08-20 | 2011-02-24 | The Regents Of The University Of Colorado, A Body Corporate | Mirnas dysregulated in triple-negative breast cancer |
RU2578719C9 (ru) | 2010-04-21 | 2016-10-10 | Синтарга Б.В. | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры |
EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
CA2832387A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
DK2764351T3 (en) | 2011-09-29 | 2019-01-28 | Seattle Genetics Inc | Determination of intact mass of protein-conjugated drug compounds |
CN116236569A (zh) * | 2011-10-14 | 2023-06-09 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2814512A1 (en) | 2012-02-16 | 2014-12-24 | UCL Business Plc. | Lysosome-cleavable linker |
PL3069735T3 (pl) | 2014-01-10 | 2018-08-31 | Synthon Biopharmaceuticals B.V. | ADC duokarmycyny do zastosowania w leczeniu raka pęcherza |
PL3092010T3 (pl) | 2014-01-10 | 2019-01-31 | Synthon Biopharmaceuticals B.V. | Sposób oczyszczania połączonych cysteiną koniugatów przeciwciało-lek |
CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
PE20170517A1 (es) * | 2014-04-30 | 2017-05-18 | Pfizer | Conjugados de anticuerpo-farmaco-anti-ptk7 |
PL3151865T3 (pl) | 2014-05-22 | 2022-01-03 | Byondis B.V. | Koniugacja w określonym miejscu leków-łączników z przeciwciałami oraz powstałe w jej wyniku koniugaty przeciwciało-lek (ADCs) |
PL3152191T3 (pl) | 2014-06-05 | 2019-10-31 | Synthon Biopharmaceuticals Bv | Ulepszony sposób wytwarzania proleków duokarmycyny |
EP3197919A1 (en) | 2014-09-22 | 2017-08-02 | Synthon Biopharmaceuticals B.V. | Pan-reactive antibodies to duocarmycins |
JP6522806B2 (ja) | 2015-07-10 | 2019-05-29 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 抗体デュオカルマイシン薬物複合体を含む組成物 |
-
2015
- 2015-01-09 CA CA2935430A patent/CA2935430C/en active Active
- 2015-01-09 HU HUE15700211A patent/HUE029672T2/en unknown
- 2015-01-09 MY MYPI2016001213A patent/MY189713A/en unknown
- 2015-01-09 JP JP2016563255A patent/JP6224268B2/ja active Active
- 2015-01-09 PT PT157002114T patent/PT2948183T/pt unknown
- 2015-01-09 KR KR1020167021532A patent/KR20160099725A/ko not_active IP Right Cessation
- 2015-01-09 DK DK15700211.4T patent/DK2948183T3/en active
- 2015-01-09 KR KR1020227010636A patent/KR20220045075A/ko not_active Application Discontinuation
- 2015-01-09 RU RU2016132635A patent/RU2686085C2/ru active
- 2015-01-09 ES ES15700211.4T patent/ES2578831T3/es active Active
- 2015-01-09 EP EP15700211.4A patent/EP2948183B1/en active Active
- 2015-01-09 AU AU2015205588A patent/AU2015205588B2/en active Active
- 2015-01-09 PL PL15700211T patent/PL2948183T3/pl unknown
- 2015-01-09 CN CN201580004140.9A patent/CN105899237B/zh active Active
- 2015-01-09 MX MX2016009069A patent/MX368234B/es active IP Right Grant
- 2015-01-09 SG SG11201605597VA patent/SG11201605597VA/en unknown
- 2015-01-09 WO PCT/EP2015/050332 patent/WO2015104373A2/en active Application Filing
- 2015-09-18 US US14/859,221 patent/US9427480B2/en active Active
-
2016
- 2016-07-01 CY CY20161100612T patent/CY1117712T1/el unknown
- 2016-07-06 HR HRP20160797TT patent/HRP20160797T1/hr unknown
- 2016-07-07 CL CL2016001743A patent/CL2016001743A1/es unknown
- 2016-07-21 US US15/216,366 patent/US10092659B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160008487A1 (en) | 2016-01-14 |
CL2016001743A1 (es) | 2017-01-06 |
EP2948183A2 (en) | 2015-12-02 |
US20170007717A1 (en) | 2017-01-12 |
RU2016132635A3 (zh) | 2018-08-13 |
PL2948183T3 (pl) | 2017-03-31 |
KR20160099725A (ko) | 2016-08-22 |
ES2578831T3 (es) | 2016-08-01 |
MX368234B (es) | 2019-09-25 |
CY1117712T1 (el) | 2017-05-17 |
DK2948183T3 (en) | 2016-06-27 |
AU2015205588B2 (en) | 2019-08-08 |
PT2948183T (pt) | 2016-07-13 |
HUE029672T2 (en) | 2017-03-28 |
JP6224268B2 (ja) | 2017-11-01 |
AU2015205588A1 (en) | 2016-07-28 |
RU2016132635A (ru) | 2018-02-16 |
JP2017502086A (ja) | 2017-01-19 |
WO2015104373A3 (en) | 2015-09-03 |
CA2935430C (en) | 2018-09-18 |
US9427480B2 (en) | 2016-08-30 |
EP2948183B1 (en) | 2016-04-06 |
CN105899237B (zh) | 2019-09-03 |
MY189713A (en) | 2022-02-28 |
RU2686085C2 (ru) | 2019-04-24 |
US10092659B2 (en) | 2018-10-09 |
HRP20160797T1 (hr) | 2016-08-12 |
CN105899237A (zh) | 2016-08-24 |
MX2016009069A (es) | 2017-02-06 |
WO2015104373A2 (en) | 2015-07-16 |
CA2935430A1 (en) | 2015-07-16 |
KR20220045075A (ko) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160797T1 (hr) | Duokarmicin adsc, namijenjen upotrebi u liječenju raka endometrija | |
HRP20180876T1 (hr) | Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura | |
ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
IL251630A0 (en) | Combined therapy for use in cancer treatment | |
IL276733A (en) | Use of Aribolin in cancer treatment | |
HUE053654T2 (hu) | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére | |
HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
IL251905B (en) | Epilimod for use in the treatment of kidney cancer | |
IL251903B (en) | Epilimod for use in the treatment of colon cancer | |
IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
ZA201403006B (en) | Composition for use in treatment of cancer | |
GB201410695D0 (en) | Uses of oligouronates in cancer treatment | |
GB201418640D0 (en) | Agents and methods for treatment of cancer |